Literature DB >> 34674120

Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article.

Farshid Etaee1, Morgan Tobin2, Suchith Vuppala3, Alireza Komaki4, Brian P Delisle5, Luigi Di Biase6, John N Catanzaro7, Andrea Natale8, Claude S Elayi9,10.   

Abstract

BACKGROUND/
PURPOSE: Mortality associated with prescription opioids has significantly increased over the past few decades and is considered a global pandemic. Prescribed opioids can cause cardiac arrhythmias, leading to fatal outcomes and unexpected death, even in the absence of structural cardiac disease. Despite the extent of cardiac toxicity and death associated with these medications, there is limited data to suggest their influences on cardiac electrophysiology and arrhythmias, with the exception of methadone. The goal of our review is to describe the possible mechanisms and to review the different ECG changes and arrhythmias that have been reported.
METHODS: A literature search was performed using Google Scholar, PubMed, Springer, Ovid, and Science Direct to identify studies that demonstrated the use of prescription opioids leading to electrocardiogram (ECG) changes and cardiac arrhythmias.
RESULTS: Many of the commonly prescribed opioid medications can uniquely effect the ECG, and can lead to the development of various cardiac arrhythmias. One of the most significant side effects of these drugs is QTc interval prolongation, especially when administered to patients with a baseline risk for QTc prolongation. A prolonged QTc interval can cause lethal torsades de pointes and ventricular fibrillation. Obtaining an ECG at baseline, following a dosage increase, or after switching an opioid medication, is appropriate in patients taking certain prescribed opioids. Opioids are often used first line for the treatment of acute and chronic pain, procedural sedation, medication opioid use disorders, and maintenance therapy.
CONCLUSIONS: To reduce the risk of cardiac arrhythmias and to improve patient outcomes, consideration of accurate patient selection, concomitant medications, electrolyte monitoring, and vigilant ECG monitoring should be considered.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac arrhythmia; Electrocardiogram; Opioid agonist; Opioid antagonist; QT prolongation, torsades de pointes

Mesh:

Substances:

Year:  2021        PMID: 34674120     DOI: 10.1007/s10840-021-01072-1

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  77 in total

Review 1.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.

Authors:  Stephen C Harris; Joel Morganroth; Steven R Ripa; Michael D Thorn; Salvatore Colucci
Journal:  Postgrad Med       Date:  2017-01       Impact factor: 3.840

Review 3.  Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review.

Authors:  Mori J Krantz; Robert B Palmer; Mark C P Haigney
Journal:  J Am Coll Cardiol       Date:  2021-01-19       Impact factor: 24.094

4.  Ventricular arrhythmias in patients treated with methadone for opioid dependence.

Authors:  Sam Hanon; Randy M Seewald; Felix Yang; Paul Schweitzer; Jonathan Rosman
Journal:  J Interv Card Electrophysiol       Date:  2010-02-23       Impact factor: 1.900

Review 5.  Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).

Authors:  R L Deamer; D R Wilson; D S Clark; J G Prichard
Journal:  J Addict Dis       Date:  2001

Review 6.  Opioids and Cardiac Arrhythmia: A Literature Review.

Authors:  Mina Behzadi; Siyavash Joukar; Ahmad Beik
Journal:  Med Princ Pract       Date:  2018-08-02       Impact factor: 1.927

7.  Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status.

Authors:  M Douglas Anglin; Bradley T Conner; Jeffery Annon; Douglas Longshore
Journal:  Addiction       Date:  2007-09       Impact factor: 6.526

8.  A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.

Authors:  J Wolstein; M Gastpar; T Finkbeiner; C Heinrich; R Heitkamp; T Poehlke; N Scherbaum
Journal:  Pharmacopsychiatry       Date:  2009-01-19       Impact factor: 5.788

9.  A community-based evaluation of sudden death associated with therapeutic levels of methadone.

Authors:  Sumeet S Chugh; Carmen Socoteanu; Kyndaron Reinier; Justin Waltz; Jonathan Jui; Karen Gunson
Journal:  Am J Med       Date:  2008-01       Impact factor: 4.965

10.  Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial.

Authors:  H Wieneke; H Conrads; J Wolstein; F Breuckmann; M Gastpar; R Erbel; Norbert Scherbaum
Journal:  Eur J Med Res       Date:  2009-01-28       Impact factor: 2.175

View more
  1 in total

Review 1.  Non-Opioid Peptides Targeting Opioid Effects.

Authors:  Katarzyna Kaczyńska; Piotr Wojciechowski
Journal:  Int J Mol Sci       Date:  2021-12-19       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.